These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21802331)

  • 1. [Expected limits (and possible consequences) of pathogen inactivation technology].
    Lefrère JJ
    Transfus Clin Biol; 2011 Aug; 18(4):468-71. PubMed ID: 21802331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen Reduction Technology in Transfusion: Where Do We Stand?
    Khurshid M; Moiz B
    J Coll Physicians Surg Pak; 2015 Nov; 25(11):779-80. PubMed ID: 26577959
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pathogen inactivation technologies: a complex but necessary debate].
    Andreu G; Cazenave JP; Garraud O; Lefrère JJ
    Transfus Clin Biol; 2011 Aug; 18(4):443. PubMed ID: 21783399
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pathogen reduction: a clinician view].
    Socié G
    Transfus Clin Biol; 2011 Aug; 18(4):491-2. PubMed ID: 21715208
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pathogen inactivation of platelets: organization consequences for platelet transfusion].
    Chavarin P; DePutter C; Boussoulade F; Acquart S; Vidal M; Argaud C; Fabrigli P; Garraud O
    Transfus Clin Biol; 2011 Aug; 18(4):472-7. PubMed ID: 21783400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen reduction: state of reflection in Ireland.
    Murphy WG
    Transfus Clin Biol; 2011 Aug; 18(4):488-90. PubMed ID: 21803629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials for pathogen reduction in transfusion medicine: a review.
    McClaskey J; Xu M; Snyder EL; Tormey CA
    Transfus Apher Sci; 2009 Dec; 41(3):217-25. PubMed ID: 19793679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving blood safety and patient outcomes with pathogen reduction technology.
    Goodrich RP; Ettinger A; Radziwon PM; Rock G
    Transfus Apher Sci; 2011 Dec; 45(3):229-38. PubMed ID: 22078570
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bacterial detection leading to pathogen inactivation].
    Morel P; Deschaseaux M; Naegelen C; Bardiaux L; des Floris MF; Pouthier F
    Transfus Clin Biol; 2005 Jun; 12(2):142-9. PubMed ID: 15894506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual risks of blood transfusion in Rhode Island.
    Sweeney JD; Kurtis J; Starakiewicz J
    Med Health R I; 2005 Jul; 88(7):224-5, 228-31. PubMed ID: 16184827
    [No Abstract]   [Full Text] [Related]  

  • 11. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pathogen reduction of blood components: from financial issues to possible long-term consequences].
    Canellini G; Wasserfallen JB; Tissot JD
    Transfus Clin Biol; 2011 Aug; 18(4):493-7. PubMed ID: 21719339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogen inactivation processes applicable to cellular products: the Canadian perspective].
    Delage G
    Transfus Clin Biol; 2011 Aug; 18(4):485-7. PubMed ID: 21715210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogen reduction for platelets: a debate].
    Moncharmont P; Py JY
    Transfus Clin Biol; 2011 Aug; 18(4):498-501. PubMed ID: 21715209
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolution of microbial safety.
    Barbara JA
    Hematol J; 2004; 5 Suppl 3():S69-73. PubMed ID: 15190282
    [No Abstract]   [Full Text] [Related]  

  • 16. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Blajchman MA
    Transfus Clin Biol; 2009 May; 16(2):70-4. PubMed ID: 19427252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Component pathogen inactivation: a critical review.
    Prowse CV
    Vox Sang; 2013 Apr; 104(3):183-99. PubMed ID: 23134556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the microbiological safety of blood for transfusion: a US perspective.
    Dodd R
    Future Microbiol; 2009 Sep; 4(7):807-18. PubMed ID: 19722836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen inactivation technology: cleansing the blood supply.
    Klein HG
    J Intern Med; 2005 Mar; 257(3):224-37. PubMed ID: 15715679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.